Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979533 | PMC |
http://dx.doi.org/10.3389/fpls.2023.1143689 | DOI Listing |
Background: Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity and was well tolerated in a phase 3 study in patients aged 2-11 years with mild to moderate atopic dermatitis (AD).
Objective: This study examined the safety, tolerability, pharmacokinetics, efficacy, and quality of life (QoL) with ruxolitinib cream under maximum-use conditions and with longer-term use.
Methods: Eligible patients were aged 2-11 years with moderate to severe AD [Investigator's Global Assessment (IGA) score 3-4], and ≥ 35% affected body surface area (BSA).
Int Urogynecol J
January 2025
Sector of Urogynecology, Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil.
J Am Geriatr Soc
January 2025
Department of Neurology, Washington University in St. Louis, St. Louis, Missouri, USA.
Front Microbiol
December 2024
National Center for Structural Biology and Bioimaging, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Recent research has focused on the prognostic relevance of preoperative sarcopenia and sarcopenic obesity in various cancers. In this study we investigated the relationship between visceral fat area (VFA), psoas muscle area (PMA), and the prognosis of patients undergoing colorectal cancer surgery.
Methods: Patients with stage III colorectal cancer who underwent surgery between July 2013 and April 2020 were included.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!